3. Improving drug safety
How to avoid the risks of drugs in routine care?
Despite careful clinical testing of new drugs, uncertainties about their safety remain even after market approval. This applies, for example, to unknown risks in persons who are often excluded or underrepresented in clinical trials, such as pregnant women, children, or older persons. In the case of already known risks, the question is whether these risks are adequately considered by prescribers and whether recommendations for risk minimization are followed. Based on health insurance data that reflects actual healthcare provision, we examine drug safety in everyday healthcare. A particular focus of our research is on drug utilization and safety during pregnancy. In addition, we conduct studies requested by health authorities, often in collaboration with international partners.
Current Projects
Only currently running projects or those where publications are still in preparation or those that ended less than a year ago will be shown. The entries are sorted alphabetically.
- PAS-study for Brodalumab
- PAS-study for galcanezumab
- PAS-study for romosozumab
- PAS-study for solriamfetol
- Prescribing of oral acitretin, alitretinoin and isotretinoin to girls and women of childbearing age and during pregnancy in Germany
- Trends in prescriptions of fluoroquinolones in Germany
- Use of anticoagulants in pediatric patients in Germany
